Paresh Vyas Selected Research

enasidenib

12/2023	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
11/2021	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
1/2019	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
1/2018	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
10/2017	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
10/2017	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paresh Vyas Research Topics

Disease

33	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2023 - 06/2010
18	Neoplasms (Cancer) 11/2023 - 06/2006
15	Leukemia 11/2023 - 01/2011
12	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2023 - 09/2010
8	Down Syndrome (Down's Syndrome) 01/2021 - 04/2004
6	Thrombocytopenia (Thrombopenia) 10/2022 - 06/2005
4	Anemia 11/2023 - 11/2005
4	Myeloproliferative Disorders (Myeloproliferative Disorder) 01/2021 - 04/2004
4	Residual Neoplasm 01/2018 - 10/2009
4	Hemorrhage 10/2016 - 06/2005
4	Acute Megakaryoblastic Leukemia (Leukemia, Megakaryocytic) 02/2007 - 04/2004
3	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 09/2010
3	Bone Marrow Failure Disorders 10/2016 - 10/2015
2	Neutropenia 11/2021 - 01/2021
2	Melanoma (Melanoma, Malignant) 04/2012 - 09/2010
2	Acute Promyelocytic Leukemia 01/2011 - 11/2010
1	Disease Progression 10/2022
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 08/2022
1	Pneumonia (Pneumonitis) 11/2021
1	Febrile Neutropenia 11/2021
1	Starvation 11/2021
1	Infections 01/2021
1	Multiple Myeloma 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 10/2020
1	Nausea 01/2020
1	Dizziness (Lightheadedness) 01/2020
1	Fatigue 01/2020
1	Body Weight (Weight, Body) 01/2020
1	Acute Erythroblastic Leukemia (Erythroleukemia) 01/2020
1	Diarrhea 01/2020
1	Asthenia 01/2020
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2019
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2018
1	Hyperbilirubinemia 10/2017
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2017
1	Thalassemia 01/2017
1	Hemolysis 01/2017
1	Transfusion Reaction 10/2016

Drug/Important Bio-Agent (IBA)

14	Azacitidine (5 Azacytidine)FDA Link 12/2023 - 09/2010
9	Transcription Factors (Transcription Factor)IBA 01/2023 - 02/2007
6	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 12/2023 - 10/2017
6	enasidenibIBA 12/2023 - 10/2017
6	GATA1 Transcription FactorIBA 01/2021 - 04/2004
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2006
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 02/2005
3	venetoclaxIBA 01/2023 - 10/2020
3	ChromatinIBA 01/2023 - 01/2019
3	glasdegibIBA 08/2022 - 10/2020
2	magrolimabIBA 11/2023 - 01/2023
2	Monoclonal AntibodiesIBA 11/2023 - 01/2023
2	ivosidenibIBA 01/2023 - 01/2021
2	isocitric acid (isocitrate)IBA 01/2023 - 01/2019
2	ArginaseIBA 11/2021 - 08/2013
2	Histones (Histone)IBA 11/2021 - 01/2019
2	Arginine (L-Arginine)FDA Link 11/2021 - 01/2019
2	Lenalidomide (CC 5013)FDA Link 01/2021 - 09/2010
2	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2020 - 10/2020
2	RNA Splicing FactorsIBA 01/2018 - 06/2017
2	recombinant FVIIa (rFVIIa)FDA Link 10/2016 - 01/2016
2	Fibrinogen (Factor I)FDA Link 10/2016 - 01/2016
2	Thrombopoietin (c-mpl Ligand)IBA 10/2016 - 01/2016
2	Peptides (Polypeptides)IBA 02/2016 - 06/2006
2	AntigensIBA 04/2012 - 09/2010
1	Gemtuzumab (Mylotarg)FDA Link 11/2023
1	Hemoglobins (Hemoglobin)IBA 11/2023
1	eltrombopag FDA Link 10/2022
1	TubulinIBA 08/2022
1	Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA 11/2021
1	CitrullineIBA 11/2021
1	EnzymesIBA 01/2021
1	cc-486IBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 01/2021
1	Hydroxyethyl Starch Derivatives (Pentastarch)FDA Link 01/2021
1	pomalidomideIBA 01/2021
1	ZincIBA 11/2020
1	fms-Like Tyrosine Kinase 3IBA 10/2020
1	AnthracyclinesIBA 10/2020
1	luspaterceptIBA 01/2020
1	HematinicsIBA 01/2020
1	Proto-Oncogene Proteins c-etsIBA 01/2019
1	EPZ-5676IBA 01/2019
1	Indicators and Reagents (Reagents)IBA 01/2018
1	Vorinostat FDA Link 11/2017
1	GlobinsIBA 01/2017
1	Factor XIII (Coagulation Factor XIII)IBA 10/2016
1	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 10/2016
1	InterleukinsIBA 10/2016
1	AntibodiesIBA 10/2016

Therapy/Procedure

18	Therapeutics 12/2023 - 09/2010
9	Stem Cell Transplantation 01/2021 - 06/2010
5	Drug Therapy (Chemotherapy) 08/2022 - 11/2005
2	Induction Chemotherapy 11/2023 - 11/2016
2	Homologous Transplantation 11/2023 - 04/2012
2	Platelet Transfusion (Blood Platelet Transfusions) 10/2016 - 01/2016
2	Transplantation 02/2016 - 04/2012
2	Cell Transplantation 02/2015 - 01/2015
1	Remission Induction 10/2020
1	Immunotherapy 01/2019
1	Transjugular Intrahepatic Portasystemic Shunt 01/2019
1	Hematopoietic Stem Cell Transplantation 01/2019